Trimethobenzamide HCl
产品说明书
 |
同义名 : | 盐酸曲美苄胺 ;Ro 2-9578; Trimethobenzamide (hydrochloride); Trimethobenzamide hydrochloride |
| CAS号 : | 554-92-7 | |
| 货号 : | A148362 | |
| 分子式 : | C21H29ClN2O5 | |
| 纯度 : | 98% | |
| 分子量 : | 424.92 | |
| MDL号 : | MFCD00057999 | |
| 存储条件： |
Pure form Inert atmosphere, 2-8°C In solvent -20°C:3-6个月-80°C:12个月 |
|
| 溶解度 : | - | |
| 动物实验配方： |
| 生物活性 | |||
|---|---|---|---|
| 描述 | Trimethobenzamide HCl is a blocker of the D2 receptor. Trimethobenzamide is an antiemetic used to prevent nausea and vomiting. Trimethobenzamide is a (non-phenothiazine) benzamide antiemetic that acts centrally to block D2 receptors, thereby inhibiting the medullary chemoreceptor trigger zone by blocking emetic impulses to the vomiting center[1]. Trimethobenzamide was shown to be significantly better than placebo in relieving periodic and total nausea over the 48-hour study. Vomiting incidence was also reduced in the group receiving trimethobenzamide[2]. Trimethobenzamide HCl was found to have more toxic and teratogenic potential on embryonic growth and development in cultured rat embryos[3]. Open-label studies suggest that the combination of trimethobenzamide and diphenhydramine (TMB/DPH) may provide effective relief in a high proportion of migraineurs[4]. In utero TMB (Trimethobenzamide) exposure may cause growth retardation, neurological damage in the developing brain and intestine, and hepatic damage[5]. | ||
| 临床研究 | |||||
|---|---|---|---|---|---|
| NCT号 | 适应症或疾病 | 临床期 | 招募状态 | 预计完成时间 | 地点 |
| NCT00626327 | Meningococcal Infections | Phase 3 | Completed | - | - |
| NCT00626327 | - | Completed | - | - | |
| NCT00806195 | - | Completed | - | - | |
| 实验方案 | |||
|---|---|---|---|
| 1mg | 5mg | 10mg | |
|
1 mM 5 mM 10 mM |
2.35mL 0.47mL 0.24mL |
11.77mL 2.35mL 1.18mL |
23.53mL 4.71mL 2.35mL |
| 参考文献 |
|---|
|
[1]Smith HS, Cox LR, Smith BR. Dopamine receptor antagonists. Ann Palliat Med. 2012;1(2):137‐142 |